GENE AND CELL THERAPIES TARGETING CNS DISORDERS MARKET ANALYSIS

Gene and Cell Therapies Targeting CNS Disorders Market, by Therapy Type (Gene Therapy and Cell Therapy), by Indication (Alzheimer's Disease (AD), Huntington's Disease (HD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease, Multiple Sclerosis (MS), Adrenoleukodystrophy & Metachromatic Leukodystrophy, Neuropathies, and Batten Disease (BD)), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Dec 2024
Code : CMI4705
Formats :
Excel and PDF
Industry : Pharmaceutical

Gene And Cell Therapies Targeting Cns Disorders MarketSize and Trends

Gene and Cell Therapies Targeting CNS Disorders Market- Dynamics

Key market players emerging into licensing and inventory agreements, is expected to drive the market growth during the forecast period. For instance, in August 2020, Taysha Gene Therapies and Abeona Therapeutics Inc., announced that they entered into licence and inventory purchase agreements for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease (also known as infantile Batten disease).

In addition, increasing collaboration of key market players for development of gene editing therapy is projected to spur the market growth during the forecast period. For instance, in June 2021, CRISPR Therapeutics is signing a deal with private company Capsida Biotherapeutics to cooperate on treatments for amyotrophic lateral sclerosis (ALS) and nerve disorder. The partners want to use Capsida's technology to better target on central nervous system tissues. CRISPR will create the gene editing tools for both initiatives, while Capsida will design the viral protein shells that will transport the medicines.

Moreover, the rising innovations in gene therapy to reverse neurological deficiencies for cell reprogramming is anticipated to boost the market growth during the forecast period. For instance, in July 2021, according to, The Ohio State University Wexner Medical Center and The Ohio State University College of Medicine, an innovative gene therapy approach is assisting children born with aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disease that causes significant physical and developmental impairments. The findings of this study reveal the results of a targeted delivery of gene therapy to the midbrain to treat a rare fatal neurodevelopmental condition in children with a neurogenetic disease, aromatic L-amino acid decarboxylase (AADC) deficiency which is characterized by dopamine and serotonin synthesis deficiencies.